Literature DB >> 30953717

Vasculature submucosal changes at early stages of osteonecrosis of the jaw (ONJ).

Ioannis Gkouveris1, Danny Hadaya1, Akrivoula Soundia1, Olga Bezouglaia1, Yee Chau1, Sarah M Dry2, Flavia Q Pirih3, Tara L Aghaloo4, Sotirios Tetradis5.   

Abstract

Osteonecrosis of the jaw (ONJ), a rare, but potentially severe side effect of anti-resorptive medications, presents as exposed bone in the maxillofacial region lasting for at least 8 weeks. While clinical experience and animal models concur in finding that systemic antiresorptive treatment in conjunction with local risk factors, such as tooth extraction or dental disease may lead to ONJ development, the subclinical molecular changes that precede bone exposure remain poorly understood. The identification of these changes is not only important in understanding disease pathophysiology, but could provide potential for treatment development. Here, we evaluated the early stages of ONJ utilizing a model of experimental periodontitis (EP) in mice treated with two different types of antiresorptives, targeting potential changes in vasculature, hypoxia, oxidative stress, and apoptosis. Antiresorptive treatment in animals with EP increased levels of empty osteocytic lacunae and increased ONJ prevalence compared to Veh animals. The arteriole and venule network seen around EP areas was diminished in animals treated with antiresorptives. Higher levels of vascular endothelial growth factor A (VEGF-A) and vascular cell adhesion protein-1 (VCAM-1) were observed 1-week following EP in treated animals. Finally, levels of hypoxia, oxidative stress, and apoptosis remained high in antiresorptive treated animals with EP through the duration of the experiment. Together, our data point to subclinical vasculature organizational disturbances that subsequently affect levels of hypoxia, oxidative stress, and apoptosis in the area of developing ONJ.
Copyright © 2019. Published by Elsevier Inc.

Entities:  

Keywords:  Anti-resorptives; Bisphosphonates; Osteoclasts; Osteonecrosis of the jaw

Mesh:

Substances:

Year:  2019        PMID: 30953717      PMCID: PMC6763394          DOI: 10.1016/j.bone.2019.03.031

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  46 in total

Review 1.  Medication-Related Osteonecrosis of the Jaw: Basic and Translational Science Updates.

Authors:  Matthew R Allen
Journal:  Oral Maxillofac Surg Clin North Am       Date:  2015-08-13       Impact factor: 2.802

2.  Oncologic doses of zoledronic acid induce osteonecrosis of the jaw-like lesions in rice rats (Oryzomys palustris) with periodontitis.

Authors:  J Ignacio Aguirre; Mohammed P Akhter; Donald B Kimmel; Jennifer E Pingel; Alyssa Williams; Marda Jorgensen; Lakshmyya Kesavalu; Thomas J Wronski
Journal:  J Bone Miner Res       Date:  2012-10       Impact factor: 6.741

3.  Vascular endothelial growth factor expression of intercellular adhesion molecule 1 (ICAM-1), vascular cell adhesion molecule 1 (VCAM-1), and E-selectin through nuclear factor-kappa B activation in endothelial cells.

Authors:  I Kim; S O Moon; S H Kim; H J Kim; Y S Koh; G Y Koh
Journal:  J Biol Chem       Date:  2000-12-06       Impact factor: 5.157

4.  Osteonecrosis of the jaws (ONJ) in mice after extraction of teeth with periradicular disease.

Authors:  Akrivoula Soundia; Danny Hadaya; Navid Esfandi; Rafael Scaf de Molon; Olga Bezouglaia; Sarah M Dry; Flavia Q Pirih; Tara Aghaloo; Sotirios Tetradis
Journal:  Bone       Date:  2016-06-18       Impact factor: 4.398

Review 5.  Vascular endothelial growth factor signaling in hypoxia and inflammation.

Authors:  S Ramakrishnan; Vidhu Anand; Sabita Roy
Journal:  J Neuroimmune Pharmacol       Date:  2014-03-09       Impact factor: 4.147

6.  Definition of bone necrosis by the pathologist.

Authors:  Cristina Fondi; Alessandro Franchi
Journal:  Clin Cases Miner Bone Metab       Date:  2007-01

7.  The effect of nitrogen containing bisphosphonates, zoledronate and alendronate, on the production of pro-angiogenic factors by osteoblastic cells.

Authors:  S Ishtiaq; S Edwards; A Sankaralingam; B A J Evans; C Elford; M L Frost; I Fogelman; G Hampson
Journal:  Cytokine       Date:  2014-11-17       Impact factor: 3.861

8.  Rheumatoid Arthritis Exacerbates the Severity of Osteonecrosis of the Jaws (ONJ) in Mice. A Randomized, Prospective, Controlled Animal Study.

Authors:  Rafael Scaf de Molon; Chingyun Hsu; Olga Bezouglaia; Sarah M Dry; Flavia Q Pirih; Akrivoula Soundia; Fernando Queiroz Cunha; Joni Augusto Cirelli; Tara L Aghaloo; Sotirios Tetradis
Journal:  J Bone Miner Res       Date:  2016-05-04       Impact factor: 6.741

9.  A retrospective study assessing the incidence, risk factors and comorbidities of pamidronate-related necrosis of the jaws in multiple myeloma patients.

Authors:  F Jadu; L Lee; M Pharoah; D Reece; L Wang
Journal:  Ann Oncol       Date:  2007-09-05       Impact factor: 32.976

10.  American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw--2014 update.

Authors:  Salvatore L Ruggiero; Thomas B Dodson; John Fantasia; Reginald Goodday; Tara Aghaloo; Bhoomi Mehrotra; Felice O'Ryan
Journal:  J Oral Maxillofac Surg       Date:  2014-05-05       Impact factor: 2.136

View more
  10 in total

1.  Inhibition of HMGB1/RAGE Signaling Reduces the Incidence of Medication-Related Osteonecrosis of the Jaw (MRONJ) in Mice.

Authors:  Ioannis Gkouveris; Danny Hadaya; Naseim Elzakra; Akrivoula Soundia; Olga Bezouglaia; Sarah M Dry; Flavia Pirih; Tara Aghaloo; Sotirios Tetradis
Journal:  J Bone Miner Res       Date:  2022-07-11       Impact factor: 6.390

Review 2.  Preclinical models of medication-related osteonecrosis of the jaw (MRONJ).

Authors:  J I Aguirre; E J Castillo; D B Kimmel
Journal:  Bone       Date:  2021-09-11       Impact factor: 4.398

3.  Local RANKL delivery improves socket healing in bisphosphonate treated rats.

Authors:  Akrivoula Soundia; Danny Hadaya; Yee Chau; Ioannis Gkouveris; Olga Bezouglaia; Sarah Dry; Flavia Pirih; Tara Aghaloo; Sotirios Tetradis
Journal:  Bone       Date:  2021-04-07       Impact factor: 4.626

Review 4.  Macrophage Involvement in Medication-Related Osteonecrosis of the Jaw (MRONJ): A Comprehensive, Short Review.

Authors:  Ioannis Gkouveris; Akrivoula Soundia; Panagiotis Gouveris; Dionysia Zouki; Danny Hadaya; Sotirios Tetradis
Journal:  Cancers (Basel)       Date:  2022-01-10       Impact factor: 6.575

5.  Intravenous Transplantation of Human Hair Follicle-Derived Mesenchymal Stem Cells Ameliorates Trabecular Bone Loss in Osteoporotic Mice.

Authors:  Longshuai Lin; Enjun He; Hongjie Wang; Weihong Guo; Zhenkai Wu; Kai Huang; Qinghua Zhao
Journal:  Front Cell Dev Biol       Date:  2022-03-10

Review 6.  Establishment and assessment of rodent models of medication-related osteonecrosis of the jaw (MRONJ).

Authors:  Ran Yan; Ruixue Jiang; Longwei Hu; Yuwei Deng; Jin Wen; Xinquan Jiang
Journal:  Int J Oral Sci       Date:  2022-08-10       Impact factor: 24.897

7.  Macrophage miR-149-5p induction is a key driver and therapeutic target for BRONJ.

Authors:  Xin Shen; Weiwen Zhu; Ping Zhang; Yu Fu; Jie Cheng; Laikui Liu; Rongyao Xu; Hongbing Jiang
Journal:  JCI Insight       Date:  2022-08-22

8.  Zoledronic Acid Deteriorates Soft and Hard Tissue Healing of Murine Tooth Extraction Sockets in a Dose-Dependent Manner.

Authors:  Ryohei Kozutsumi; Shinichiro Kuroshima; Haruka Kaneko; Muneteru Sasaki; Akira Ishisaki; Takashi Sawase
Journal:  Calcif Tissue Int       Date:  2021-08-07       Impact factor: 4.333

9.  Prospective Observational Study of Bisphosphonate-Related Osteonecrosis of the Jaw in Multiple Myeloma: Microbiota Profiling and Cytokine Expression.

Authors:  Ashraf Z Badros; Mariam Meddeb; Dianna Weikel; Sunita Philip; Todd Milliron; Rena Lapidus; Lisa Hester; Olga Goloubeva; Timothy F Meiller; Emmanuel F Mongodin
Journal:  Front Oncol       Date:  2021-06-24       Impact factor: 6.244

10.  Preventive effect of fluvastatin on the development of medication-related osteonecrosis of the jaw.

Authors:  Naomi Adachi; Yasunori Ayukawa; Noriyuki Yasunami; Akihiro Furuhashi; Mikio Imai; Koma Sanda; Ikiru Atsuta; Kiyoshi Koyano
Journal:  Sci Rep       Date:  2020-03-27       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.